Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

被引：0

作者：

Jeroen J. A. van Kampen

David A. M. C. van de Vijver

Pieter L. A. Fraaij

Bart L. Haagmans

Mart M. Lamers

Nisreen Okba

Johannes P. C. van den Akker

Henrik Endeman

Diederik A. M. P. J. Gommers

Jan J. Cornelissen

Rogier A. S. Hoek

Menno M. van der Eerden

Dennis A. Hesselink

Herold J. Metselaar

Annelies Verbon

Jurriaan E. M. de Steenwinkel

Georgina I. Aron

Eric C. M. van Gorp

Sander van Boheemen

Jolanda C. Voermans

Charles A. B. Boucher

Richard Molenkamp

Marion P. G. Koopmans

Corine Geurtsvankessel

Annemiek A. van der Eijk

机构：

[1] Erasmus MC,Department of Viroscience

[2] Subdivision Infectious Diseases and Immunology,Department of Pediatrics

[3] Erasmus MC - Sophia,Department of Intensive Care

[4] Erasmus MC,Department of Hematology

[5] Erasmus MC,Department of Pulmonary Medicine

[6] Erasmus MC,Department of Internal Medicine, Division of Nephrology and Transplantation

[7] Erasmus MC Transplant Institute,Department of Gastroenterology and Hepatology

[8] Erasmus MC,Department of Medical Microbiology and Infectious Diseases

[9] Erasmus MC,undefined

[10] Erasmus MC,undefined

来源：

Nature Communications | / 12卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Key questions in COVID-19 are the duration and determinants of infectious virus shedding. Here, we report that infectious virus shedding is detected by virus cultures in 23 of the 129 patients (17.8%) hospitalized with COVID-19. The median duration of shedding infectious virus is 8 days post onset of symptoms (IQR 5–11) and drops below 5% after 15.2 days post onset of symptoms (95% confidence interval (CI) 13.4–17.2). Multivariate analyses identify viral loads above 7 log10 RNA copies/mL (odds ratio [OR] of 14.7 (CI 3.57-58.1; p < 0.001) as independently associated with isolation of infectious SARS-CoV-2 from the respiratory tract. A serum neutralizing antibody titre of at least 1:20 (OR of 0.01 (CI 0.003-0.08; p < 0.001) is independently associated with non-infectious SARS-CoV-2. We conclude that quantitative viral RNA load assays and serological assays could be used in test-based strategies to discontinue or de-escalate infection prevention and control precautions.

引用

共 30 条

[1]

Huang C(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 395 497-506

[2]

Zhu N(2020)China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019 N. Engl. J. Med. 382 727-733

[3]

Docherty AB(2020)ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study BMJ 369 m1985-1105

[4]

Anderson RM(2004)Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic Philos. Trans. R. Soc. Lond. B Biol. Sci. 359 1091-1043

[5]

Ling Y(2020)Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients Chin. Med. J. (Engl.). 133 1039-30190

[6]

Liu WD(2020)Prolonged virus shedding even after seroconversion in a patient with COVID-19 J. Infect. S0163-4453 30190-2666

[7]

Bullard J(2020)Predicting infectious SARS-CoV-2 from diagnostic samples Clin. Infect. Dis. 71 2663-694

[8]

Munster VJ(2020)A novel coronavirus emerging in China—key questions for impact assessment N. Engl. J. Med. 382- 692-657

[9]

Koopmans M(2020)Viral dynamics in mild and severe cases of COVID-19 Lancet Infect. Dis 20 656-327

[10]

van Doremalen N(2020)Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study BMJ 369 m1443-675

← 1 2 3 →